Figure 5
Figure 5. Cellular origin of TF-exposing vesicles in saliva and plasma. Microparticles (A,C,E) and exosomes (B,D,F) were isolated from saliva (A-B,E-F) and plasma (C-D) by differential centrifugation, labeled, and analyzed by flow cytometry as outlined in “Flow cytometry.” To establish the cellular origin, antibodies were used directed against CD66b (granulocytes), Ema (epithelial membrane antigen, epithelial cells), CD61 (integrin β3, platelets, possibly granulocytes in saliva), CD235a (glycophorin A, erythrocytes), and CD20 (B lymphocytes), or control antibody (IgG). Microparticles (E) and exosomes (F) from saliva were double-labeled with anti-TF plus antibodies against either CD66b or Ema, and analyzed by flow cytometry. (A-D) Data are number of microvesicles per milliliter. (E-F) Data are expressed as percentage of the total number of TF-exposing microparticles or TF-exposing exosomes (n = 10).

Cellular origin of TF-exposing vesicles in saliva and plasma. Microparticles (A,C,E) and exosomes (B,D,F) were isolated from saliva (A-B,E-F) and plasma (C-D) by differential centrifugation, labeled, and analyzed by flow cytometry as outlined in “Flow cytometry.” To establish the cellular origin, antibodies were used directed against CD66b (granulocytes), Ema (epithelial membrane antigen, epithelial cells), CD61 (integrin β3, platelets, possibly granulocytes in saliva), CD235a (glycophorin A, erythrocytes), and CD20 (B lymphocytes), or control antibody (IgG). Microparticles (E) and exosomes (F) from saliva were double-labeled with anti-TF plus antibodies against either CD66b or Ema, and analyzed by flow cytometry. (A-D) Data are number of microvesicles per milliliter. (E-F) Data are expressed as percentage of the total number of TF-exposing microparticles or TF-exposing exosomes (n = 10).

Close Modal

or Create an Account

Close Modal
Close Modal